Nintedanib

This week, the FDA approves single-use bronchoscopes; a study finds the Moderna COVID-19 vaccine is safe and effective in adolescents; CMS nixes the most-favored nation pricing model for Medicare Part B; and more.

Adoption of pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis has been low in the U.S., according to an analysis published in the Annals of the American Thoracic Society.

Following the recent approvals of nintedanib and tocilizumab for systemic sclerosis-related interstitial lung disease, providers should manage the disease based on severity, progression risk and extrapulmonary activity, noted researchers.

Sofosbuvir, mirabegron and nintedanib — all approved within the past 9 years — are among the drugs associated with the highest disproportionate reporting of ANCA-associated vasculitis, according to data.

In patients with idiopathic pulmonary fibrosis, antifibrotic treatment may reduce the risk for all-cause mortality and acute exacerbations, according to a systematic review and meta-analysis published in Chest.

In the SENSCIS-ON trial, two-thirds of patients with systemic sclerosis-associated interstitial lung disease who continued nintedanib after completion of the SENSCIS trial maintained stable lung function or had improvement in lung function.

A number of new therapies, including immunosuppressive drugs and drug combinations, have shown efficacy in mitigating scleroderma-associated interstitial lung disease, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

New analyses of the INBUILD trial show nintedanib slowed lung function decline and reduced the annual rate of FVC decline in patients with a progressive form of chronic fibrosing interstitial lung diseases, including in various subgroups.

Nintedanib appeared safe and effective for the treatment of advanced nonpancreatic neuroendocrine tumors, according to results of a phase 2 study published in Cancer.